TABLE 3.

Factor associations with vestibular screening failures

		Vestibular Fail
Covariate	Level	No (N=20)	Yes (N=30)	Odds Ratio	Parametric P-value*
Gender	Male	12 (42.86)	16 (57.14)	0.762	0.642
	Female	8 (36.36)	14 (63.64)
Diagnosis	Brain tumor	8 (25.81)	23 (74.19)	4.929	0.009
	No brain tumor	12 (63.16)	7 (36.84)
Age at Diagnosis	Median (range)	5.5 (0.7–15.4)	7.0 (0.4–16.2)	1.121	0.096
Brain surgery	No	11 (57.89)	8 (42.11)	0.298	0.043
	Yes	9 (29.03)	22 (70.97)
Radiation to head/neck	No	7 (46.67)	8 (53.33)	0.675	0.529
	Yes	13 (37.14)	22 (62.86)
Cisplatin	No	15 (48.39)	16 (51.61)	0.381	0.122
	Yes	5 (26.32)	14 (73.68)
Carboplatin	No	11 (30.56)	25 (69.44)	4.090	0.029
	Yes	9 (64.29)	5 (35.71)
Vancomycin	No	16 (43.24)	21 (56.76)	0.375	0.247
	Yes	2 (22.22)	7 (77.78)
Aminoglycosides	No	18 (41.86)	25 (58.14)	0.000	0.151
	Yes	0 (0)	3 (100)
Hearing loss	No	12 (48.00)	13 (52.00)	0.451	0.228
	Yes	5 (29.41)	12 (70.59)
Years after total treatment	Median (range)	5.9 (0.2–13.9)	2.8 (0.2–10.6)	0.812	0.018

^*The parametric p-value was calculated by univariate logistic regression (for Age at diagnosis and Years after total treatment) or chi-square test (for all others).